

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

INSIDE INFORMATION
COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated (i) December 15, 2025 in relation to the proposed implementation of H Share Full Circulation program by the Company; (ii) May 8, 2026 in relation to the issuance of Filing Notice by the CSRC for the H Share Full Circulation and proposed implementation of H Share Full Circulation by the Company; and (iii) May 14, 2026 in relation to the approval granted by the Stock Exchange for the listing of and permission to deal in the Converted H Shares (collectively, the “**Announcements**”). Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that the conversion of an aggregate of 44,391,598 Unlisted Shares into H Shares was completed on June 4, 2026 and the Converted H Shares were listed on the Stock Exchange at 9:00 a.m. on June 5, 2026.

The shareholding structure of the Company immediately before and upon completion of the Conversion and Listing is set out as follows:

Type of shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	Number of shares	Approximate percentage of total issued shares of the Company	Number of shares	Approximate percentage of total issued shares of the Company
Unlisted Shares	45,613,109	22.93%	1,221,511	0.61%
H Shares	153,278,691	77.07%	197,670,289	99.39%
Total	198,891,800	100.00%	198,891,800	100.00%

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
 南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
 Chief Executive Officer*

Nanjing, PRC, June 5, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.